CD19 and B-cell chronic lymphocytic leukemia: A key breakthrough in the clinical success of CAR-T cell therapy was achieved in 2011 when Dr. Carl June and his team demonstrated clinical responses in patients with chronic lymphocytic leukemia (CLL) who received 2G CAR-T cells targeting CD19 (16, 17).